Ambrisentan for in pediatric pulmonary arterial hypertension: A cost‐utility analysis

Introduction Despite the growing evidence of efficacy, little is known regarding the efficiency of ambrisentan to decrease cost and improve the functional classes of pediatric patients with pulmonary arterial hypertension. This study aims to determine the cost‐utility of ambrisentan regarding silden...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Pediatric pulmonology 2023-05, Vol.58 (5), p.1562-1568
Hauptverfasser:	Buendía, Jefferson A., Patiño, Diana G., Lindarte, Erika F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Child Colombia Cost-Benefit Analysis covid‐19 Familial Primary Pulmonary Hypertension - drug therapy health economics healthcare Humans Hypertension, Pulmonary - drug therapy Pediatrics public health Pulmonary Arterial Hypertension - drug therapy Pulmonary hypertension Quality of Life Sildenafil Citrate - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!